Shortly after WuXi AppTec provided an upbeat outlook for 2025, several other WuXi sibling companies are coming forward with ...

WuXi Biologics (2269.HK), a leading global CRDMO, has once again earned top recognition at the 2025 CDMO Leadership Awards, ...

WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced it ...

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) ...

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "We are very pleased to be named once again on the CDP Water Security 'A' list, an acknowledgement that further ...

Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are honored to receive the CDMO Leadership Award for the eighth consecutive year. This achievement reflects the trust of our global partners ...

according to Chris Chen Zhisheng, CEO of Wuxi Biologics, its largest drugs development and manufacture outsourcing company.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are excited to upgrade our microbial solutions with the innovative EffiX™ platform, which offers our clients exceptional productivity and ...

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "We are very pleased to be once again selected for inclusion in the Yearbook, a reflection of our steadfast ...

The firm said it would focus on producing vaccines at its facilities in China. WuXI Biologics CEO Chris Chen has denied the sale was a result of geopolitical problems, according to Pharmaceutical ...